RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

NCT04844086 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped CAR-T manufacturing technology can not meet the dose requirement for clinical patients.

Conditions

B-cell Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma, Relapsed
Non-Hodgkin's Lymphoma Refractory
Primary Mediastinal Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
High-grade B-cell Lymphoma

Interventions

BIOLOGICAL: RPM CD19-mbIL15-CAR-T cells

Sponsor

Eden BioCell Ltd.

Collaborators

[object Object]